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impairment of neutrophils
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G€O€OS ET AL 1365Arg219His mutation identified in a Finnish family with
previously genetically uncharacterized autoinflammatory and
immunodeficiency syndrome.
Methods: Genetic analysis, proteomics, genome-wide
transcriptional profiling by means of RNA-sequencing,
chromatin immunoprecipitation (ChIP) sequencing, and
assessment of the inflammasome function of primary
macrophages were performed.
Results: Studies revealed a novel mechanism of genome-wide
gain-of-function that dysregulated transcription of 464 genes.
Mechanisms involved dysregulated noncanonical inflammasome
activation caused by decreased association with transcriptional
repressors, leading to increased chromatin occupancy and
considerable changes in transcriptional activity, including
increased expression of NLR family, pyrin domain-containing 3
protein (NLRP3) and constitutively expressed caspase-5 in
macrophages.
Conclusion: We describe a novel autoinflammatory disease with
defective neutrophil function caused by a homozygous
Arg219His mutation in the transcription factor C/EBPε.
Mutated C/EBPε acts as a regulator of both the inflammasome
and interferome, and the Arg219His mutation causes the first
human monogenic neomorphic and noncanonical
inflammasomopathy/immunodeficiency. The mechanism,
including widely dysregulated transcription, is likely not unique
for C/EBPε. Similar multiomics approaches should also be used
in studying other transcription factor–associated diseases. (J
Allergy Clin Immunol 2019;144:1364-76.)
Key words: Immunologic deficiency syndromes, autoinflammatory
diseases, hereditary, chemotaxis, interferons, inflammasomes, NLR
family, pyrin domain-containing 3 protein, gain-of-function muta-
tion, neomorphic mutation
Primary immunodeficiencies (PIDs) are caused by inherent
defects in the immune system and offer a unique glimpse into
regulation of the human immune system. Findings in patients with
PIDs can help in development of treatments for immune
dysregulation, which is known to lead to various common
diseases, including atherosclerosis, asthma, and diabetes.1 Of
the more than 350 currently known PIDs, approximately 20 are
caused by germline autosomal dominant gain-of-function
(GOF) mutations.2-4 In general, GOF mutations can be caused
by hyperactivating or neomorphic mechanisms. To date, all
known GOF PIDs have been hypermorphic (ie, resulting in
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Many autoinflammatory diseases (AIDs), such as cryopyrino-
pathies, are driven by activation of the canonical NLR family, pyrin
domain-containing 3 protein (NLRP3) inflammasome through
production of the highly proinflammatory IL-1b and IL-18. The
noncanonical caspase-4/5 (murine ortholog, caspase-11) inflam-
masome is a recently discovered inflammasome activated by
intracellular bacterial LPS and involved in first-line defense against
gram-negative bacteria. Similar to canonical activation, noncanon-
ical inflammasome activation results in increased IL-1b and IL-18
production.5 In mice induction of caspase-11 expression by type I
interferon signaling is required for activation of the noncanonical
inflammasome.6-9 In human subjects local activation of the nonca-
nonical inflammasome has been shown to contribute to the patho-
genesis of age-related macular degeneration.10 However, the
potential role of the noncanonical inflammasome in systemic hu-
man diseases remains to be explored.
The CCAAT enhancer–binding protein epsilon (C/EBPε),
encoded byCEBPE, is a transcription factor expressed in myeloid
and lymphoid lineage cells and is known to be involved in cellular
differentiation and function of late myeloid lineages.11 The onlyReceived for publication November 2, 2018; revised May 6, 2019; accepted for publica-
tion June 4, 2019.
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1366 G€O€OS ET ALpreviously known CEBPE-associated disorder, autosomal
recessive neutrophil-specific granule deficiency (SGD), is caused
by frameshift mutations resulting in abrogation of at least 2 of the
4 known C/EBPε isoforms. This leads to a complete loss of
specific neutrophilic granules and consequently to severely
impaired neutrophil function with pronounced susceptibility to
bacterial infections and early mortality.12,13 A milder autosomal
dominant CEBPE (Val218Ala) variant leads to total SGD with
recurrent deep-seated abscesses.14 Early studies in Cebpe
knockout mice showed Cebpe to be integral for maintenance of
constitutive levels of several cytokines, including IFN-g.15
We report an autosomal recessiveGOFPID, C/EBPε-associated
autoinflammation and immune impairment of neutrophils (CAIN),
in a family with a genetically uncharacterized autoinflammatory
syndrome.16-18 According to our results, C/EBPε acts as a regu-
lator of both the inflammasome and interferome. Homozygous
missense mutations in CEBPE (14:23586886 C->T;p.Arg219His)
resulted inmarkedly decreasedC/EBPε associationwith transcrip-
tional repressors and increased occupancy on chromatin, leading
to dysregulated C/EBPε-mediated transcription of interleukin
and interferon response genes in neutrophils. Patients’ macro-
phages displayed aberrant caspase-5–mediated activation of the
noncanonical inflammasome pathway. Patients withCAINdisplay
a loss-of-function (LOF) mechanism in protein-protein interac-
tions (PPIs) and a novel GOF mechanism in DNA binding and
transcriptional regulation. Furthermore, CAIN is the first PID
and systemic AID involving a noncanonical inflammasome.METHODS
Written informed consent was obtained from study participants, and the
study was approved by the institutional ethical review board (138/13/03/00/
2013).
DNA from 3 affected family members (Fig 1, A) were analyzed by using
whole-exome sequencing, and Sanger sequencing was further used to confirm
the mutation status of the other family members. Before whole-exome
sequencing was available, patients were tested against LBR, MVK, and
NLRP3 mutations; no rare cosegregated variants in known AID genes were
noted. Further details of the genetic analysis are available in the Methods
section in this article’s Online Repository at www.jacionline.org.Functional studies of CEBPE mutation
Flp-In T-REx 293 cell lines stably expressing mutant or wild-type (WT)
C/EBPε were generated and used to investigate PPIs by using proximity-
dependent biotin identification coupled to mass spectrometry, as described by
Liu et al19 and in the Methods section in this article’s Online Repository.Functional studies of patients’ primary cells
Granulocytes were isolated from 2 homozygous patients, 2 heterozygous
carriers, and 3 sex- and age-matched control subjects, and chromatin
immunoprecipitation sequencing (ChIP-seq) was used to assess C/EBPε
binding to chromatin in freshly isolated and LPS-stimulated cells.
RNA sequencing (RNA-seq) was used for genome-wide transcriptional
profiling of freshly isolated untreated granulocytes from patients and control
subjects. Given the clinical phenotype of increased bacterial infections, we
also used 59-end RNA-seq to identify genes differentially expressed after 3
different stimulations: (1) DNA extracted from Pseudomonas aeruginosa,
(2) LPS extracted from P aeruginosa, or (3) LPS extracted from Escherichia
coli. Moreover, granulocytes were stimulated with IFN-a2 and IFN-g,
followed by transcriptional profile analysis using 59-end RNA-seq.
Nanostring20 analysis was used for direct digital detection of the mRNA
levels of selected genes from PBMCs.Caspase-5 levels were analyzed by using quantitative PCR and Western
blotting to access inflammasome activation and inflammasome-mediated
cytokine secretion more deeply. Caspase-1 activity was measured by using
flow cytometry from blood immune cells, and IL-1b/IL-18 secretion was
measured by using ELISA from cultured macrophages.
We also assessed granule exocytosis, granulocyte responsiveness, and
neutrophilic and monocytic nuclear factor kB (NF-kB) phosphorylation using
flow cytometry. Subcellular morphology of granulocytes and granule
abundance of platelets were assessed by using transmission electron micro-
scopy, as well as Wright staining of granulocytes. Further details of the
methods are available in theMethod section in this article’s OnlineRepository.RESULTS
Case reports
In the 1970s, affectedmembers of the index familywere thought
to have atypical Pelger-Hu€et anomaly because they presented with
neutrophil hyposegmentation, aberrant neutrophil responsiveness,
and impaired chemotaxis.16-18 Patients experienced recurrent at-
tacks of abdominal pain, aseptic fever, and systemic inflammation
lasting 4 to 5 days. These were accompanied by an acute-phase
response and occasionally by nailbed, tongue, submandibular
and gluteal abscesses; intra-abdominal granulomas; pyoderma
gangrenosum; and buccal ulcerations. Furthermore, they experi-
enced frequent episodes of purulent paronychia complicated by
lymphangitis, superficial skin, andmucosal and purulent upper res-
piratory tract infections. Their autoinflammatory symptoms mani-
fested more clearly during puberty and subsided after menopause
(Table I). All affectedmembers further had mild bleeding diathesis
with frequent nosebleeds and a tendency toward hematomas after
needle sticks and procedures. Extended case reports are available
in this article’s Online Repository at www.jacionline.org.Genetic analysis found a novel homozygous CEBPE
mutation
To identify the causative mutation, we analyzed DNA from 3
surviving members (II.2, II.7, and II.13) of the index family by
performing whole-exome sequencing. In exome data we identi-
fied between 20,638 and 21,313 single nucleotide variants and
small insertions/deletions in each patient. A total of 149 variants
were very rare (ie, those not seen in the 6500National Heart Lung,
and Blood Institute Exomes 1000 Genomes database [April 2012
data release] and 2500 exomes analyzed internally by using the
same bioinformatics pipeline). Of these, 22 variants were shared
between all 3 patients. Only one of these variants was homozy-
gous in all 3 patients (ENSG00000092067:ENST00000206513:
exon2:c.G656A;p.Arg219His) in the CEPBE gene. The novel
homozygous CEBPE 14:23586886 C>T mutation cosegregated
perfectly with the disease phenotype (Fig 1, A, and see Fig E1
in this article’s Online Repository at www.jacionline.org).16-18
Arg219His was predicted to be detrimental and not listed in major
public or in-house databases. It resided in the highly conserved
basic zipper region’s carboxyl terminal DNA-binding domain
shared by all 4 C/EBPε isoforms (Fig 1,B andC).11,21,22 Identified
homozygous or heterozygous novel germline mutations were
validated by using Sanger sequencing (Fig 1, A).Widely altered C/EBPε PPIs
To understand the functional effects of the p.Arg219His
mutation, we assayed PPIs of WT and mutant C/EBPε using
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FIG 1. Pedigree of the index family and changes in PPIs. A, Pedigree of the index family with the C/EBPε Ar-
g219His mutation. Homozygous subjects are shown in red, heterozygous carriers are shown in orange, and
deceased subjects are indicated by diagonal bars. B, Three-dimensional structure of a C/EBPε dimer (blue
and red helixes) bound to a DNA fragment. The top right panel shows the WT Arg219-DNA interaction,
and the right bottom panel shows the mutated 219His interaction. C, Schematic illustration showing the Ar-
g219His mutation within the basic zipper (bZIP) region of the DNA-binding domain of C/EBPε.D, C/EBPε PPIs
detected by using proximity-dependent biotin identification coupled to mass spectrometry. Interacting pro-
teins were classified by using the CORUM and UniProt databases, and the complex and/or functional group
membership are depicted by different colors. Novel interactions are shown with red edges, and the 2 pre-
viously known C/EBPε interactions are shown in blue. E, The Arg219His mutation in C/EBPε causes
decreased associations with transcriptional repressors. Log2 FCs of PPIs (mean, n 5 4) between Arg219His
and WT C/EBPε are shown. Color coding highlights the transcription regulation action (UniProt) of proteins
with more than 2-fold decrease in interaction (log2 FC < 21).
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TABLE I. Clinical characteristic of patients
Patient II.2 II.7 II.13
Age at onset of symptoms 17 y 17 y Youth
Current age Deceased at age 78 y 74 y 69 y
Main symptoms Abdominal pain, high fever
Crater-like ulcers of buccal
mucosa occasionally during
periodic fever
Abdominal pain, high fever Abdominal pain, high fever
Crater-like ulcers of buccal
mucosa occasionally during
periodic fever
Duration of attacks (average) 4-5 d 4-5 d 4-5 d
Frequency of attacks (average) Every 2-4 wk, later more seldom Every 2-4 wk, later more seldom Every 2-4 wk, later more seldom
Other symptoms during attacks Lymphangitis
Vomiting
Myalgia
Pleurisy
Arthralgia
Ileitis diagnosed by laparotomy
Lymphangitis
Pleurisy
Episcleritis
Scleritis Aphthous colitis
Lymphangitis
Vomiting
Myalgia
ESR (mm/h) at attacks 70-80 >50 70-80
Other major clinical events Myocardial infarction at age 46 y Operated on for ileal
leiomyosarcoma at age 35 y
Pyoderma gangrenosum at age
43 y
Mesenterial lymph node biopsy
at laparotomy at age 55 y
showed granulomatous
inflammation
Recurrent respiratory tract
infections since age 42 y
Laparotomy at age 55 y showed
ileitis and mesenterial lymph
node biopsy granulomatous
inflammation
Infections Severe recurrent tongue abscesses when very young
Easily acquired purulent wounds with delayed healing
Paronychia
Gluteal and submandibular abscesses
Bleeding diathesis Moderately severe nose bleeds, as well as need for prolonged compression after needle sticks
Postoperative hematomas
In addition, patient II.3 was likely a carrier with similar systemic symptoms, periodic fever, and skin and mucosal sequelae. At age 18 years, she acquired rheumatic fever, causing
mitral and aortic valve insufficiency and cardiac arrhythmias. At age 23 years, she had subacute endocarditis caused by Streptococcus viridans and died at age 34 years of
ventricular fibrillation. Postmortem autopsy showed ‘‘substantial’’ numbers of calcified mesenteric lymph nodes with ‘‘nonspecific inflammation.’’
ESR, Erythrocyte sedimentation rate.
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1368 G€O€OS ET ALproximity-dependent biotin identification coupled to mass
spectrometry (see Fig E2, A, in this article’s Online Repository
at www.jacionline.org). This identified 144 C/EBPε interaction
partners, 141 of which were previously not reported (Fig 1, D,
and see Table E1 in this article’s Online Repository at
www.jacionline.org). Based on quantitative interaction analysis,
108 PPIs were significantly (P < .05) altered; 106 showed
decreased and 2 showed increased interaction with mutant
compared with WT C/EBPε (Fig 1, E, and see Table E1).
Importantly, many of the diminished interactors were transcrip-
tional repressors, suggesting widely dysregulated C/EBPε-driven
transcription (Fig 1, E, and see Table E1). Twenty-four of the
novel interactions were also seen in Jurkat T cells (see Table
E1). We observed similar loss of transcriptional repressors
when analyzing the mouse Arg219His C/EBPε mutant,
suggesting a high degree of conservation of C/EBPε functions
and effects of the mutation (Fig E2, B).15
One of the known interactions was C/EBPε interaction to
SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin re-
modeling complex subunit SMARCC2 (SMRC2), which is an
important regulator of myeloid differentiation.23 This affinity
was reduced in mutant compared with WT SMRC2 (log2
Mut/WT 5 20.41). In addition to SMRC2, we found C/
EBPε to interact with 4 other SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily
members (SNF5, SMRD1, SMRD2, and SMCE1), all of which
were downregulated in patients compared with control subjects
(see Table E1).
To see how specific the changes in PPIs were for the
Arg219His-mutated C/EBPε, we generated a cell line expressing
Val218Ala C/EBPε, which is known to cause SGD,14,24 and
compared the interaction changes between these 2 mutants (see
Fig E2, C, and Table E1). Most of the studied interactions did
not differ between Val218Ala and WT C/EBPε.Increased chromatin occupancy of Arg219His C/
EBPε
Mapping of the p.Arg219His mutation to the DNA-binding
domain of C/EBPε prompted us to profile the chromatin
occupancy of C/EBPε. We performed ChIP-seq from granulo-
cytes without and with LPS stimulation (Fig 2 and see Table E2 in
this article’s Online Repository at www.jacionline.org). Peak call-
ing and overlap analysis from biological replicates revealed
3391 C/EBPε-binding sites in control subjects, 4686 in Ar-
g219His heterozygote carriers, and 10322 in homozygous pa-
tients (Fig 2, A). Similar results were observed on LPS
stimulation (Fig 2, B). Increased occupancy was also evident in
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FIG 2. ChIP-seq analysis of C/EBPε DNA binding.A and B, Area-proportional Venn diagrams of C/EBPε ChIP-
seq binding sites and tag density maps of C/EBPε-binding events flanking 6 5 kb in the absence (Fig 2, A)
and presence (Fig 2, B) of LPS treatment. C, Average C/EBPε ChIP-seq signal profiles. D, Binding motif, as
determined by using ChIP-seq. No significant changes were seen in the binding site of the Arg219His
mutant. All ChIP-seq experiments were carried out in freshly isolated human granulocytes. C, Control sub-
jects; Ca, heterozygous carriers; P, homozygous patients.
J ALLERGY CLIN IMMUNOL
VOLUME 144, NUMBER 5
G€O€OS ET AL 1369
FIG 3. Transcriptomic analysis of unstimulated (A-C) and bacterial LPS- and DNA-stimulated (D-F) granulo-
cytes using RNA-seq. Fig 3, A, RNA-seq revealed 464 differentially transcribed genes (FC > 2 and FDR < 0.05)
between the patients and control subjects in unstimulated granulocytes. Of these, 198 (Fig 3, C) were iden-
tified to be interferon related by using Interferome (version 2.01, www.interferome.org), and 271 (Fig 3, D)
had C/EBPε-binding sites (mapping to nearby genes within650 kb). Importantly, 80 of these 271 genes were
associated with patient-specific C/EBPε binding. Fig 3,D, Similarly, 470 genes were differentially transcribed
in bacterial LPS- and DNA- stimulated granulocytes. Fig 3, E and F, Of these, 183 (Fig 3, E) were identified to
be interferon related, and 289 (Fig 3, F) had C/EBPε binding-sites. Eighty-one genes had patient-specific C/
EBPε binding. Volcano plots represent log2 FCs and 2log10 FDRs of transcripts between the patients and
control subjects. Different groups are color coded. C, Control subjects; Ca, heterozygous carriers; P, homo-
zygous patients.
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novo motif analyses identified highly similar consensus
DNA-binding sequences in WT and mutant C/EBPε (Fig 2, D).This suggests that the increased C/EBPε chromatin occupancy
was caused by mechanisms other than the altered DNA-binding
motifs usually seen in neomorphisms.25
FIG 4. Transcriptomic analysis of IFN-a2–stimulated (A and B) and IFN-g–stimulated (C and D) granulocytes
by using RNA-seq. Fig 4, A, RNA-seq revealed 534 differentially transcribed genes (FC > 2 and FDR < 0.05)
between patients and control subjects after IFN-a2 stimulation. Fig 4, B, Of these, 266 had C/EBPε-binding
sites (mapping to nearby genes within 650 kb), and importantly, 83 of these were associated with patient-
specific C/EBPε binding. Fig 4, C, Similarly, 427 genes were differentially transcribed in IFN-g–stimulated
granulocytes. Fig 4, D, Of these, 208 had C/EBPε-binding sites, with 54 being associated with patient-
specific C/EBPε binding. Volcano plots represent log2 FCs and 2log10 FDRs of transcripts between patients
and control subjects. Different groups are color coded. C, Control subjects; Ca, heterozygous carriers; P, ho-
mozygous patients.
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unstimulated granulocytes
Increased mutant C/EBPε binding to DNA and decreased
association with transcription repressors can lead to dysregulated
transcriptome. Thus we compared transcriptomes of patients with
CAIN and control subjects in unstimulated granulocytes using
RNA-seq (Fig 3, A). This identified 464 significantly differen-
tially transcribed (fold change [FC] >_ 2 or <_ 0.5, false discovery
rate [FDR] <_ 0.05) genes, 198 of which, including NLRP3
(FC 5 8.25), were interferon related (Fig 3, B, and see Table
E3 in this article’s Online Repository at www.jacionline.org).
Furthermore, Gene Ontology analysis revealed upregulation
of genes involved in inflammatory responses, transcription,
chemotaxis, and LPS response (see Table E4 in this article’s
Online Repository at www.jacionline.org). One of the upregu-
lated genes was PRTN3, which encodes the ubiquitous, espe-
cially in neutrophils, serine protease proteinase 3.26 Activated
neutrophils secrete PR3, which, among its other functions,
cleaves structural proteins and activates the inflammasome-
regulated cytokines IL-1b and IL-18.26,27 Upregulation of
PRTN3 was verified by using RT-PCR (see Fig E3, A, in this
article’s Online Repository at www.jacionline.org). CEBPE
was not among the differentially expressed genes in granulo-
cytes; even slightly increased expression was detected by using
RT-PCR in PBMCs (see Fig E3, B).
To investigate whether these differentially transcribed genes
were under C/EBPε control, we mapped ChIP-seq peaks to
nearby genes within 650 kb range and performed overlapanalysis. Of the 464 differentially expressed genes, 271 had
C/EBPε-binding sites, and importantly, 80 genes had patient-
specific binding (Fig 3, C, and see Table E3). We noted increased
occupancy and novel C/EBPε-binding sites in patients for
overexpressed inflammasome-interleukin–related genes (eg,
NLRP3 [see Fig E4, A, in this article’s Online Repository at
www.jacionline.org], NFKBIA, and IL1R2), suggesting aberrant
inflammasome activation.Comparison of results for differentially expressed
genes with those of other studies
Recently, Serwas et al24 performed a proteomics analysis of
neutrophils from patients with SGD (C/EBPε mutation p.Va-
l218Ala). They detected decreased expression of several granule
proteins and increased expression of proteins linked to the nucle-
oskeleton and cytoskeleton, such as nesprin, vimentin, and
lamin B2. Because our proteomic analysis was performed to
identify changes on PPIs and not changes in the proteome, we
compared the differentially expressed proteins from Serwas
et al with our differentially expressed genes in RNA-seq exper-
iments. In our data, opposite to proteins of patients with SGD,
nesprin-2 (SYNE2) was detected with decreased expression in
neutrophils from patients with CAIN (see Table E3). Vimentin
was detected with a 2.2-fold increase in patients with CAIN,
but because of an FDR of 0.09 it was filtered out from the differ-
entially expressed genes (FDR cutoff5 0.05). Lamin B2 was not
differentially expressed in RNA-seq analysis, but we found
AB
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E
FIG 5. Transcriptomic analysis and characterization of changes in inflammasome activation. A, mRNA
levels of PBMCs from patients and subjects analyzed by using Nanostring technology. Custom gene panel
with selected inflammasome, interleukin, JAK/STAT, and NF-kB1 pathway–related genes were used in anal-
ysis, and average FCs of 3 technical replicates are presented. Statistically significant changes (Student t test)
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see Table E3).
Serwas et al24 also identified lactotransferrin and neutrophil
gelatinase-associated lipocalin to be downregulated in patients
using both proteomics methods and quantitative PCR.24 In
RNA-seq experiments in patients with CAIN, lactotransferrin
levels were also decreased (FC 5 0.34), although with a high
FDR value of 0.84. Similarly, LCN2 levels were slightly
decreased but with a high FDR value.
Khanna-Gupta et al14 detected increased expression of PU.1
and decreased expression of Gfi-1 in neutrophils from patients
with SGD (C/EBPε mutation Val218Ala). We did not find Gfi-1
(GFI) and PU.1 (SPI1) to interact with C/EBPε in PPI analysis.
However, PU.1 expression was detected in RNA-seq, but it did
not show changes between patients with CAIN and healthy
control subjects (data not shown). Gfi-1 expression was not found
in RNA-seq analysis.
The clinical characters of patients with different C/EBPε
mutations or SGD are compared in Table E5 in this article’s
Online Repository at www.jacionline.org.
Transcriptional changes after LPS and bacterial
DNA stimulation
Given the clinical phenotype of frequent bacterial infections
and neutrophilic skin symptoms (Table I), we stimulated patients’
granulocytes with bacterial LPS and DNA. A total of 470 genes
were found to be significantly differentially transcribed between
patients and control subjects (FC >_ 2 or <_ 0.5, FDR <_ 0.05; Fig
3, D, and see Table E6 in this article’s Online Repository at
www.jacionline.org). Of these, 183 were involved in interferon
signaling (Fig 3, E, and see Table E6). In particular, gene
transcription of the IFIT family (IFIT1, IFIT3, and IFIT5) was
decreased, and that of NLRP3 was increased in patients’ cells.
Overlap analysis between ChIP-seq–mapped genes and RNA-
seq results identified 289 of 470 differentially transcribed genes
having C/EBPε-binding sites, 81 of them showing patient-specific
binding (Fig 3, F, and see Table E6). Analogous to differentially
transcribed genes in unstimulated granulocytes, various
inflammasome-related genes, such as IL18 and NLRP3, showed
increased C/EBPε occupancy on chromatin in patients. Results
again highlight dysregulated interleukin and inflammasome
signaling in patients with CAIN.
Transcriptional changes after interferon stimulation
Dysregulated interferon signaling led us to test the direct
effects of type I (IFN-a2b) and type II (IFN-g) interferon
stimulation on granulocytes. In response to IFN-a2b stimulation,
534 genes were differentially transcribed (FC >_ 2 or <_ 0.5,
FDR <_ 0.05) between patients and control subjects (Fig 4, A,
and see Table E7, A, in this article’s Online Repository atof combined patients to control subjects are highlighte
active CASP1 were measured by using flow cytometry
some with ATP in whole blood. C-E, Peripheral blood
the Toll-like receptor ligands LPS/P3C or IFN-a2b, follo
D and E) activation of the NLRP3 inflammasome with A
IL-1b or IL-18 cytokine secretion was measured from c
expression of CASP5 mRNA in resting macrophages,
Expression of pro-caspase-5 (48 kDa) and the process
30 kDa) assessed from nonstimulated PBMC cell lysates
as FCs compared with control values are showed next t
cence intensity; P3C, Pam3Cys-SKKKK; TF, transfected.www.jacionline.org), with significant alterations in immune
response and inflammasome-related gene expression. These
included a significant 13.6-fold increase in NLRP12 expression
in patients. NLRP12, a known suppressor of neutrophil migration
and chemotaxis,28 also had increased C/EBPε occupancy on chro-
matin in patients (see Fig E4,B). Overall, 266 of 534 differentially
transcribed genes had C/EBPε-binding sites; 83 genes had
patient-specific binding (Fig 4, B, and see Table E7, A).
In response to IFN-g stimulation, 427 genes were differentially
expressed (FC >_ 2 or <_ 0.5, FDR <_ 0.05) between the patients and
control subjects (Fig 4,C, and seeTable E7,B), with significant alter-
ations in immune response and inflammasome-related genes. These
included amodest 1.7-fold increase inNLRP3 expression under both
conditions and a significant 3.8-fold increase in NLRP12 expression
after IFN-g stimulation. Comparison with ChIP-seq–mapped genes
showed that 49% (208/427) of differentially expressed genes after
IFN-g treatment had C/EBPε-binding sites. Of these, 54 showed
patient-specific binding, respectively (Fig 4, D).
Importantly, interferon-related genes, such as NLRP3, TLR4,
NLRP12, IL1RAP, and IL1R2, showed increased transcription
and C/EBPε chromatin binding in patients after IFN-a2b and
IFN-g stimulations. A similar effect was observed with IL18,
IL13RA1, IL17RA, and MEFV after IFN-a2b stimulation.mRNA levels in PBMCs
Next, we performed direct digital detection of mRNA mole-
cules using Nanostring technology. This does not require conver-
sion of mRNA to cDNA by using reverse transcription or
amplification of the resulting cDNA by using PCR. Nanostring
results showed increased mRNA levels of both Janus kinase
(JAK)/signal transducer and activator of transcription (STAT)
pathway genes and inflammasome components (eg, CASP5,
NLRP3, and CASP8), as well as dysregulation of the NF-kB
pathway (Fig 5, A). Interestingly, changes in mRNA levels were
not concordantwith autoinflammation caused by type I interferon-
opathy (see Table E8 in this article’s Online Repository at www.
jacionline.org). Importantly, inflammasome and inflammation-
related genes, such as CASP8 (Fig E5, A), NLRP3 (Fig E4, A),
NLRP12 (Fig E4, B), IL18, NFKB1, and STAT6, were found to
be significantly overexpressed with aberrantly greater C/EBPε
chromatin binding in patients.
Moreover, Arg219His-mutated C/EBPε functions as an NF-
kB2 regulator, with NF-kB2 binding only observed in patients’
cells (Fig E5, B), resulting in a 3- to 4-fold increase in NFKB2
transcription (Fig 5, A) in patients. Further studies are required
to elucidate which role C/EBPε plays in NFKB2 regulation. Our
results suggest neomorphism through enhanced chromatin
occupancy of mutant C/EBPε, leading to increased transcription,
aberrant inflammasome activation, and dysregulated interleukin,
NF-kB2, and interferon signaling.d. *P < .05, **P < .01, and ***P < .001. B, Levels of
after canonical activation of the NLRP3 inflamma-
monocyte-derived macrophages were primed with
wed by canonical (Fig 5, C) or noncanonical (Fig 5,
TP or transfection of LPS to cytoplasm, respectively.
ulture supernatants by means of ELISA. F, Relative
as determined by means of quantitative PCR. G,
ed intermediate form of caspase-5 (approximately
by using Western blotting. Quantification of bands
o the blot. AU, Arbitrary units;MFI, median fluores-
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macrophages by a noncanonical inflammasome
Differences in transcription of inflammasome components led
us to investigate functional changes in canonical and noncanon-
ical inflammasomes.We detected no differences between patients
and control subjects in whole-blood canonical NLRP3 activation
or in inflammasome-triggered caspase-1 activity in monocytes
(Fig 5, B). In cultured macrophages secretion of both IL-1b and
constitutively expressed IL-18 was similar after canonical activa-
tion (Fig 5,C) butwasmarkedly enhanced after noncanonical cas-
pase-4/5–mediated NLRP3 activation in patients compared with
control subjects (Fig 5, D and E). This was caused by aberrantly
induced caspase-5 expression in resting macrophages of patients
(Fig 5, F). In agreement with macrophage results, the increased
protein expression of pro-caspase-5 was also detected from non-
stimulated PBMCs from patients (Fig 5, G). Moreover, consider-
ably more caspase-5 was processed in the patient’s PBMCs, as
shown by a clear intermediate band of caspase-5 of approximately
30 kDa (Fig 5, G). Aberrant activation of patients’ macrophages
required no priming by interferon response because priming
with IFN-a2b instead of a Toll-like receptor agonist abolished
any differences in IL-18 expression (Fig 5, E) and CASP5
mRNA levels (see Fig E6, A, in this article’s Online Repository
at www.jacionline.org). Results further suggested increased
expression of other interferon-regulated genes (see Fig E6, B).Neutrophils displayed impaired CD66b expression
Patients were known to have impaired granulocyte function
and chemotaxis, suggesting a hypomorphic LOF mutation.16,18
We used flow cytometry to assay the expression of CD66a,
CD66b, and CD11b involved in cellular adhesion and migration
found within neutrophil granules and with a subsequent increase
in surface expression after exocytosis.29 CD66a and CD11b are
found in secondary and tertiary granules, respectively. On flow
cytometry, CD66a and CD11b expression was unaffected, which
is consistent with a non-SGD disease (see Fig E7 in this article’s
Online Repository at www.jacionline.org). Additionally, patients’
granulocytes displayed side-scattered light within the normal
range, unlike in patients with SGD.12,13
CD66b is involved in neutrophil localization and activation and
has been implicated in interaction of granulocytes with each
other. Patients’ granulocytes displayed impaired expression of
CD66b compared with those from age- and sex-matched control
subjects (see Fig E7). The aberrantly low CD66b expression
likely contributes, with increased transcription of NLRP12, to
the impaired chemotaxis previously reported.16 Taken together,
these data suggest a deficiency in specific granule function.
NF-kB plays a key role in inflammation and immune
response.30-32 Therefore we assessed NF-kB activity in whole
blood. No differences were seen in NF-kB phosphorylation at
baseline or in response to stimulation with bacterial LPS and
DNA, suggesting that their periodic inflammation was not caused
by dysregulated NF-kB activity.Normal neutrophil and platelet morphology
To determine the possible structural changes in neutrophils, we
analyzed endoplasmic reticulum size and shape and mitochon-
drial size by using transmission electron microscopy. No clear
differences were seen between patients and control subjects. Inaddition, electron microscopy showed that patients’ neutrophils
contained normal-sized azurophilic specific and tertiary granules
in normal numbers (data not shown).
Similar results were seen with staining using the Wright
method.33 From Wright-stained smears of both patients and con-
trol subjects, 200 consecutive leukocytes were studied for gran-
ules and morphology. Patients’ neutrophils presented both
primary and secondary granules, and no difference was observed
in comparison with healthy control subjects (see Fig E8, A, in this
article’s Online Repository at www.jacionline.org). However, as
seen earlier,16 20% of patients’ neutrophils were hyposegmented
(see Fig E8, B). Eosinophils and basophils also showed normal
granules compared with those of healthy control subjects.
C/EBPε is known to control platelet granule formation.15,21 Pa-
tients displayedmild bleeding diathesis, and therewe investigated
platelet morphology and platelet granule abundance in patients
with CAIN. No morphologic aberrancies were found in a granule
and overall platelets structure. Dilated open canalicular systems
were detected in both patients. Patient II.7 had some multivesic-
ular bodies, which are more common in megakaryocytes. Plate-
lets were slightly activated based on the detected pseudopodia
but mainly displayed a normal discoid form (data not shown).Posttranscriptional compensatory mechanisms
Compared with RNA-seq and ChIP-seq results, patients are
bafflingly mildly symptomatic but with mixed neomorphisms and
hypomorphisms. Analysis of heterozygous relatives without
reported clinical manifestations of disease showed intermediate
cellular changes. Thus results suggest a novel autosomal recessive
inheritance pattern in which the disease in the heterozygote state
lacks expressivity because of unknown posttranscriptional
compensatory mechanisms and requires the homozygous state
to become clinically manifest. The reduced heritability of disease
phenotype, even in the presence of the severely altered DNA
binding seen in asymptomatic carriers, likely reflects the complex
nature of compensatory mechanisms and underscores the aston-
ishing extent to which the human body can maintain homeostasis,
even in the presence of an otherwise pathogenic mutation.
To address this, we analyzed DNA methylation in patients
(n5 2) compared with control subjects and found no changes that
would explain the patients’ symptoms or the relative mildness of
them compared with RNA-seq and ChIP-seq analysis (data not
shown).
Results from RNA-seq and ChIP-seq raise the possibility that
histone methylation could be one compensatory posttranscrip-
tional mechanism. This and open chromatin binding will need to
be explored in knock-in animal models, allowing for larger
numbers of mutation carriers.DISCUSSION
We report a novel GOF mechanism caused by a transcription
factor mutation. Homozygous Arg219His CEBPEmutation leads
to CAIN, which was clinically characterized by a combination of
autoinflammation, immunodeficiency, and neutrophil dysfunc-
tion. To our knowledge, this is the first mutation to cause such
widely dysregulated transcription in patients with PIDs. It is
also the first AID that involves aberrant expression and activation
of noncanonical caspase-4/5 inflammasome. After Li-Fraumeni
syndrome, CAIN seems to be only the second germline
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tions.25 Our results highlight the potential for germline mutations
in transcription factors to causewidespread and complex genome-
wide mechanism, with only limited concomitant morbidity. Such
changes will not readily be evident by using targeted functional
assessment and typical nongenomic types of analyses, causing
probable underdiagnosis. For example, transcription factor muta-
tions with pronounced overlap between known clinical GOF and
LOF phenotypes (eg, STAT1)34 might need to be studied by using
similar data-driven systems-level approaches.
The Arg219His mutation in the DNA-binding domain of C/
EBPε was predicted to lead to loss of DNA binding and
possible LOF. However, the mutation resulted in a pronounced
increase in C/EBPε chromatin binding, likely caused by a
decreased association with multiple transcriptional repressors.
This decreased transcriptional repressor association could have
been driven by C/EBPε Arg219His–induced conformational
changes to protein structure because no difference was seen in
the consensus DNA recognition motif between control subjects
and patients. This mechanism has previously been described
for a single (not orthologous) transcriptional repressor in
patients with autosomal dominant SGD and in Drosophila
species.35
Our results reveal the role of C/EBPε in complex interlinked
signaling cascades. The reported deficiency in neutrophil
chemotaxis18 is likely caused by multiple factors, including
differentially transcribed genes (ie, CD66B; see Fig E7)
affecting cellular maturation and movement and increased
expression of NLRP12, a known suppressor of neutrophil
migration.28
Results also show that C/EBPε regulates interferon pathways
and noncanonical inflammasome target genes (eg, NLRP3,
CASP5, and IL18), further highlighting the overlap between
the inflammasome and interferon signaling. Pathway compo-
nents associated with noncanonical inflammasome activation
were aberrantly transcribed, together with decreased NF-kB1
and increased NF-kB2 and JAK/STAT components (Fig 5,
A).36 Although caspase-4 is known to be constitutively ex-
pressed, human caspase-5 expression is interferon depen-
dent.8,9,37 Notably, we found increased baseline expression of
caspase-5 in patients’ macrophages and increased IL-1b and
IL-18 secretion on stimulation of the noncanonical caspase-4/
5 inflammasome with intracellular LPS. Because of constitu-
tively expressed caspase-5, interferon priming was not required.
Consequently, IFN-a2b priming before intracellular LPS trans-
fection induced caspase-5 expression also in control cells and
thus abolished the difference in cytokine secretion between pa-
tients and control subjects (Fig 5, E, and see Fig E6, A). Thus our
data imply that the CEBPE Arg219His neomorphic mutation
was alone sufficient to maintain constitutive caspase-5 expres-
sion. This sensitized the patients’ macrophages to respond pro-
nouncedly to intracellular LPS - clinically causing
hyperinflammation after bacterial stimuli. Investigating both
the inflammasome and interferon pathways together in patients
with inflammatory conditions might lead to a deeper understand-
ing of their cause and to targeted treatments.38-40 In patients with
CAIN, anti–IL-1b and anti–IL-18 seem likely treatment modal-
ities but remain untested.
The index family has been studied since the 1970s.16-18
A systems-level approach combining genomics, transcriptom-
ics, and proteomics finally made it possible to unravel thecausative pathogenic mechanisms. In conclusion, CAIN re-
veals GOF mechanisms resulting in autoinflammation and im-
munodeficiency, which are potentially relevant for various
transcription factor–related diseases. Also, C/EBPε seems to
be involved in regulation of the noncanonical inflammasome
and interferon signaling, suggesting a novel target for drug
development. The widely dysregulated transcription seen in
asymptomatic heterozygous carriers compared with control
subjects suggests extremely effective posttranscriptional regu-
latory capacity in human subjects that requires further investi-
gation. Given their apparent roles in idiopathic inflammation,
roles of both C/EBPε and the noncanonical inflammasome
should be further explored in the context of autoimmune dis-
eases and AIDs.
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Key messages
d Patients with biallelic CEBPE (14:23586886 C>T; p.Ar-
g219His) missense mutations displayed a noncanonical
inflammasome–mediated autoinflammatory and immuno-
deficiency disease, leading to an aberrantly activated non-
canonical inflammasome.
d C/EBPε acts as a regulator of both the inflammasome and
interferome.
d We describe a novel GOF mechanism caused by a
missense transcription factor mutation, which leads to
widely dysregulated transcription. This mechanism is
most likely not unique for the transcription factor C/
EBPε, and similar multiomics approaches should be
applied in patients with other diseases associated with
transcription factors.REFERENCES
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